{"Clinical Trial ID": "NCT00313170", "Intervention": ["INTERVENTION 1:", "-Fulvestant 250 mg", "-Fulvestant 250 mg", "INTERVENTION 2:", "- Fulvestant 250 mg + loading dose", "- Fulvestant 250 mg + loading dose"], "Eligibility": ["Incorporation criteria:", "Breast cancer continued to grow after receiving hormonal anti-estrogen therapy such as tamoxifen or an aromatase inhibitor.", "- Requires hormonal treatment.", "Menopausal women (women who have ceased to have menstruation)", "- Exclusion criteria:", "Treatment with more than one previous anticancer systemic regimen other than endocrine treatment for advanced B.C.", "Treatment with more than one previous endocrine regimen for advanced B.C.", "A condition that prevents compliance."], "Results": ["Performance measures:", "- Objective response (ORR)", "The objective response rate was defined as the percentage of patients with a complete response (CR - elimination of all target lesions) or a partial response (PR - reduction of at least 30% in the sum of the diameters of target lesions).All patients were to be monitored every 12 weeks for progression, defined by criteria for assessing response in solid tumours (RECIST v1.1).", "Timeline: The data for this study was the time when all patients, with the exception of withdrawals, had been monitored for at least 24 weeks. Patients received treatment up to approximately 2 years.", "Results 1:", "Title of arm/group: Fulvestant 250 mg", "Description of the arm/group: Fulvestant 250 mg", "Total number of participants analysed: 47", "Type of measurement: Number", "Unit of measure: Percentage of patients 8.5 (2.4 to 20.4)", "Results 2:", "Title of arm/group: Fulvestant 250 mg + loading dose", "Description of the arm/group: Fulvestant 250 mg + loading dose", "Total number of participants analysed: 51", "Type of measurement: Number", "Unit of measure: Percentage of patients 5.9 (1.2 to 16.2)"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/47 (8.51 per cent)", "Anemia 0/47 (0.00 %)", "Myocardial infarction 0/47 (0.00 %)", "1/47 (2.13%)", "Intestinal diverticulum Haemorrhagic 0/47 (0.00 %)", "Melaena 0/47 (0.00 %)", "- Pain 0/47 (0.00 %)", "Pneumonia 0/47 (0.00 %)", "- Hip fracture 0/47 (0.00 %)", "Meniscus L\u00e9sion 1/47 (2.13 per cent)", "- Amnesia 0/47 (0.00 %)", "Ischemic accident 1/47 (2.13 per cent)", "- Depression 0/47 (0.00 per cent)", "Adverse Events 2:", "Total: 9/50 (18.0%)", "Anemia 1/50 (2.0%)", "Myocardial infarction 1/50 (2.0%)", "- Macular hole 0/50 (0.00 %)", "Diverticulum Intestinal Hemorrhagic 1/50 (2.0%)", "Melaena 1/50 (2.0%)", "- Pain 0/50 (0.00 %)", "Pneumonia 0/50 (0.00 %)", "- Hip fracture 0/50 (0.00 %)", "Meniscus Lesion 0/50 (0.00 %)", "- Amnesia 0/50 (0.00 %)", "Ischemic accident 0/50 (0.00 %)", "- Depression 1/50 (2.0%)"]}